nodes	percent_of_prediction	percent_of_DWPC	metapath
Minocycline—ALOX5—Sulfasalazine—ankylosing spondylitis	0.368	0.636	CbGbCtD
Minocycline—SLC22A11—Methotrexate—ankylosing spondylitis	0.0718	0.124	CbGbCtD
Minocycline—SLC22A7—Methotrexate—ankylosing spondylitis	0.0684	0.118	CbGbCtD
Minocycline—SLC22A8—Methotrexate—ankylosing spondylitis	0.0417	0.0721	CbGbCtD
Minocycline—SLC22A6—Methotrexate—ankylosing spondylitis	0.0291	0.0502	CbGbCtD
Minocycline—IL1B—synovial fluid—ankylosing spondylitis	0.0259	0.163	CbGeAlD
Minocycline—IL1B—knee—ankylosing spondylitis	0.0234	0.147	CbGeAlD
Minocycline—MMP9—synovial fluid—ankylosing spondylitis	0.0216	0.136	CbGeAlD
Minocycline—IL1B—skeletal joint—ankylosing spondylitis	0.0168	0.105	CbGeAlD
Minocycline—MMP9—skeletal joint—ankylosing spondylitis	0.014	0.0878	CbGeAlD
Minocycline—IL1B—vertebral column—ankylosing spondylitis	0.0133	0.0837	CbGeAlD
Minocycline—IL1B—synovial membrane of synovial joint—ankylosing spondylitis	0.0128	0.08	CbGeAlD
Minocycline—CASP1—Cellular roles of Anthrax toxin—ANTXR2—ankylosing spondylitis	0.0121	0.048	CbGpPWpGaD
Minocycline—IL1B—cartilage tissue—ankylosing spondylitis	0.0113	0.0708	CbGeAlD
Minocycline—MMP9—cartilage tissue—ankylosing spondylitis	0.00941	0.059	CbGeAlD
Minocycline—CASP1—Interleukin-1 processing—IL1A—ankylosing spondylitis	0.00826	0.0327	CbGpPWpGaD
Minocycline—IL1B—Cellular roles of Anthrax toxin—ANTXR2—ankylosing spondylitis	0.00759	0.03	CbGpPWpGaD
Minocycline—CASP1—IL1-mediated signaling events—IL1R2—ankylosing spondylitis	0.00686	0.0271	CbGpPWpGaD
Minocycline—CASP1—NOD1/2 Signaling Pathway—CARD9—ankylosing spondylitis	0.0064	0.0253	CbGpPWpGaD
Minocycline—IL1B—Interleukin-1 processing—IL1A—ankylosing spondylitis	0.00516	0.0204	CbGpPWpGaD
Minocycline—CASP1—NOD pathway—CARD9—ankylosing spondylitis	0.00512	0.0202	CbGpPWpGaD
Minocycline—IL1B—IL23-mediated signaling events—IL23R—ankylosing spondylitis	0.00501	0.0198	CbGpPWpGaD
Minocycline—VEGFA—Beta3 integrin cell surface interactions—EDIL3—ankylosing spondylitis	0.00438	0.0173	CbGpPWpGaD
Minocycline—CASP1—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—CARD9—ankylosing spondylitis	0.00437	0.0173	CbGpPWpGaD
Minocycline—IL1B—IL1-mediated signaling events—IL1R2—ankylosing spondylitis	0.00428	0.0169	CbGpPWpGaD
Minocycline—CYCS—Orphan transporters—ANO6—ankylosing spondylitis	0.00396	0.0156	CbGpPWpGaD
Minocycline—IL1B—Senescence and Autophagy in Cancer—CREG1—ankylosing spondylitis	0.00379	0.015	CbGpPWpGaD
Minocycline—IL1B—Interleukin-1 signaling—IL1R2—ankylosing spondylitis	0.00376	0.0149	CbGpPWpGaD
Minocycline—CASP1—IL1-mediated signaling events—IL1RN—ankylosing spondylitis	0.00324	0.0128	CbGpPWpGaD
Minocycline—VEGFA—Integrins in angiogenesis—EDIL3—ankylosing spondylitis	0.00323	0.0127	CbGpPWpGaD
Minocycline—IL1B—NOD pathway—CARD9—ankylosing spondylitis	0.0032	0.0126	CbGpPWpGaD
Minocycline—CASP1—Apoptosis Modulation and Signaling—IL1R2—ankylosing spondylitis	0.00312	0.0123	CbGpPWpGaD
Minocycline—CASP1—tendon—ankylosing spondylitis	0.00293	0.0184	CbGeAlD
Minocycline—MMP9—Validated targets of C-MYC transcriptional activation—KIR3DL1—ankylosing spondylitis	0.00276	0.0109	CbGpPWpGaD
Minocycline—CASP1—Signaling by Interleukins—IL1R2—ankylosing spondylitis	0.00272	0.0107	CbGpPWpGaD
Minocycline—CYCS—Apoptosis Modulation and Signaling—IL1R2—ankylosing spondylitis	0.00267	0.0105	CbGpPWpGaD
Minocycline—IL1B—IL27-mediated signaling events—IL17A—ankylosing spondylitis	0.00264	0.0105	CbGpPWpGaD
Minocycline—IL1B—IL27-mediated signaling events—IL12B—ankylosing spondylitis	0.00246	0.00972	CbGpPWpGaD
Minocycline—CASP3—tendon—ankylosing spondylitis	0.00242	0.0152	CbGeAlD
Minocycline—IL1B—Cytokines and Inflammatory Response—IL12B—ankylosing spondylitis	0.00239	0.00943	CbGpPWpGaD
Minocycline—CASP1—IL1-mediated signaling events—IL1A—ankylosing spondylitis	0.00233	0.00922	CbGpPWpGaD
Minocycline—CASP3—Apoptosis Modulation and Signaling—IL1R2—ankylosing spondylitis	0.00215	0.00851	CbGpPWpGaD
Minocycline—IL1B—IL1-mediated signaling events—IL1RN—ankylosing spondylitis	0.00203	0.00801	CbGpPWpGaD
Minocycline—IL1B—IL23-mediated signaling events—IL17A—ankylosing spondylitis	0.00199	0.00788	CbGpPWpGaD
Minocycline—IL1B—tendon—ankylosing spondylitis	0.00193	0.0121	CbGeAlD
Minocycline—CASP1—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.00191	0.00755	CbGpPWpGaD
Minocycline—VEGFA—tendon—ankylosing spondylitis	0.0019	0.0119	CbGeAlD
Minocycline—CASP1—Apoptosis—TNFRSF1B—ankylosing spondylitis	0.00186	0.00734	CbGpPWpGaD
Minocycline—IL1B—IL23-mediated signaling events—IL12B—ankylosing spondylitis	0.00185	0.00733	CbGpPWpGaD
Minocycline—IL1B—Interleukin-1 signaling—IL1RN—ankylosing spondylitis	0.00178	0.00703	CbGpPWpGaD
Minocycline—IL1B—Cytokines and Inflammatory Response—IL1A—ankylosing spondylitis	0.00175	0.00693	CbGpPWpGaD
Minocycline—IL1B—Cytokines and Inflammatory Response—IL10—ankylosing spondylitis	0.00174	0.00689	CbGpPWpGaD
Minocycline—CASP1—Apoptosis Modulation and Signaling—TNFRSF1B—ankylosing spondylitis	0.00174	0.00689	CbGpPWpGaD
Minocycline—IL1B—Signaling by Interleukins—IL1R2—ankylosing spondylitis	0.0017	0.00672	CbGpPWpGaD
Minocycline—CYCS—FAS pathway and Stress induction of HSP regulation—IL1A—ankylosing spondylitis	0.00169	0.00667	CbGpPWpGaD
Minocycline—MMP9—tendon—ankylosing spondylitis	0.00161	0.0101	CbGeAlD
Minocycline—CYCS—Apoptosis—TNFRSF1B—ankylosing spondylitis	0.00159	0.00628	CbGpPWpGaD
Minocycline—IL1B—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.00156	0.00616	CbGpPWpGaD
Minocycline—CYCS—Apoptosis Modulation and Signaling—TNFRSF1B—ankylosing spondylitis	0.00149	0.00589	CbGpPWpGaD
Minocycline—VEGFA—Hypertrophy Model—IL1A—ankylosing spondylitis	0.00148	0.00587	CbGpPWpGaD
Minocycline—IL1B—IL1-mediated signaling events—IL1A—ankylosing spondylitis	0.00146	0.00577	CbGpPWpGaD
Minocycline—CASP3—FAS pathway and Stress induction of HSP regulation—IL1A—ankylosing spondylitis	0.00136	0.00538	CbGpPWpGaD
Minocycline—MMP9—Endochondral Ossification—RUNX3—ankylosing spondylitis	0.00136	0.00537	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.00132	0.00521	CbGpPWpGaD
Minocycline—CASP3—Allograft Rejection—HLA-C—ankylosing spondylitis	0.00131	0.00519	CbGpPWpGaD
Minocycline—MMP9—Matrix Metalloproteinases—MMP3—ankylosing spondylitis	0.00131	0.00517	CbGpPWpGaD
Minocycline—CASP3—Posttranslational regulation of adherens junction stability and dissassembly—MMP3—ankylosing spondylitis	0.00129	0.00511	CbGpPWpGaD
Minocycline—IL1B—Type II interferon signaling (IFNG)—HLA-B—ankylosing spondylitis	0.00129	0.0051	CbGpPWpGaD
Minocycline—CASP1—Signaling by Interleukins—IL1RN—ankylosing spondylitis	0.00129	0.00508	CbGpPWpGaD
Minocycline—CASP3—Apoptosis—TNFRSF1B—ankylosing spondylitis	0.00128	0.00507	CbGpPWpGaD
Minocycline—IL1B—Hematopoietic Stem Cell Differentiation—IL1A—ankylosing spondylitis	0.00128	0.00506	CbGpPWpGaD
Minocycline—IL1B—Interleukin-1 signaling—IL1A—ankylosing spondylitis	0.00128	0.00506	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	0.00127	0.00502	CbGpPWpGaD
Minocycline—IL1B—IL12-mediated signaling events—IL12B—ankylosing spondylitis	0.00126	0.00498	CbGpPWpGaD
Minocycline—CASP1—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.00125	0.00495	CbGpPWpGaD
Minocycline—MMP9—Activation of Matrix Metalloproteinases—MMP3—ankylosing spondylitis	0.00124	0.00491	CbGpPWpGaD
Minocycline—CASP3—Apoptosis Modulation and Signaling—TNFRSF1B—ankylosing spondylitis	0.0012	0.00476	CbGpPWpGaD
Minocycline—CASP3—Allograft Rejection—IL17A—ankylosing spondylitis	0.0012	0.00475	CbGpPWpGaD
Minocycline—CYCS—p75(NTR)-mediated signaling—MMP3—ankylosing spondylitis	0.0012	0.00474	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.00119	0.00472	CbGpPWpGaD
Minocycline—CASP3—TNF alpha Signaling Pathway—TNFRSF1B—ankylosing spondylitis	0.00119	0.00471	CbGpPWpGaD
Minocycline—IL1B—Allograft Rejection—HLA-C—ankylosing spondylitis	0.00119	0.0047	CbGpPWpGaD
Minocycline—VEGFA—Endochondral Ossification—RUNX3—ankylosing spondylitis	0.00118	0.00466	CbGpPWpGaD
Minocycline—CASP3—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.00118	0.00465	CbGpPWpGaD
Minocycline—CASP3—Allograft Rejection—IL12B—ankylosing spondylitis	0.00112	0.00441	CbGpPWpGaD
Minocycline—IL1B—Allograft Rejection—IL17A—ankylosing spondylitis	0.00109	0.0043	CbGpPWpGaD
Minocycline—MMP9—Collagen degradation—MMP3—ankylosing spondylitis	0.00108	0.00428	CbGpPWpGaD
Minocycline—IL1B—Leptin signaling pathway—IL1RN—ankylosing spondylitis	0.00108	0.00425	CbGpPWpGaD
Minocycline—CASP3—Oncostatin M Signaling Pathway—MMP3—ankylosing spondylitis	0.00101	0.00401	CbGpPWpGaD
Minocycline—IL1B—Allograft Rejection—IL12B—ankylosing spondylitis	0.00101	0.00399	CbGpPWpGaD
Minocycline—MMP9—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—MMP3—ankylosing spondylitis	0.000999	0.00395	CbGpPWpGaD
Minocycline—IL1B—IL-1 signaling pathway—IL1A—ankylosing spondylitis	0.000993	0.00392	CbGpPWpGaD
Minocycline—IL1B—TCR Signaling Pathway—IL17A—ankylosing spondylitis	0.000979	0.00387	CbGpPWpGaD
Minocycline—CASP3—p75(NTR)-mediated signaling—MMP3—ankylosing spondylitis	0.000967	0.00382	CbGpPWpGaD
Minocycline—CYCS—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000966	0.00382	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000959	0.00379	CbGpPWpGaD
Minocycline—CASP1—Signaling by Interleukins—IL1A—ankylosing spondylitis	0.000926	0.00366	CbGpPWpGaD
Minocycline—IL1B—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	0.000882	0.00348	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000868	0.00343	CbGpPWpGaD
Minocycline—MMP9—Assembly of collagen fibrils and other multimeric structures—MMP3—ankylosing spondylitis	0.000842	0.00333	CbGpPWpGaD
Minocycline—IL1B—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	0.000824	0.00326	CbGpPWpGaD
Minocycline—CASP3—Allograft Rejection—IL1A—ankylosing spondylitis	0.000821	0.00325	CbGpPWpGaD
Minocycline—CASP3—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000816	0.00323	CbGpPWpGaD
Minocycline—CASP3—Allograft Rejection—IL10—ankylosing spondylitis	0.000816	0.00323	CbGpPWpGaD
Minocycline—IL1B—IL12-mediated signaling events—HLA-A—ankylosing spondylitis	0.000811	0.00321	CbGpPWpGaD
Minocycline—CASP1—Amyotrophic lateral sclerosis (ALS)—TNF—ankylosing spondylitis	0.000808	0.00319	CbGpPWpGaD
Minocycline—IL1B—Signaling by Interleukins—IL1RN—ankylosing spondylitis	0.000804	0.00318	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	0.000793	0.00314	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—HLA-C—ankylosing spondylitis	0.000791	0.00313	CbGpPWpGaD
Minocycline—CASP3—Degradation of the extracellular matrix—MMP3—ankylosing spondylitis	0.000789	0.00312	CbGpPWpGaD
Minocycline—IL1B—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.000782	0.00309	CbGpPWpGaD
Minocycline—CASP3—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000776	0.00307	CbGpPWpGaD
Minocycline—CYCS—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—ankylosing spondylitis	0.000774	0.00306	CbGpPWpGaD
Minocycline—IL1B—Allograft Rejection—IL1A—ankylosing spondylitis	0.000743	0.00294	CbGpPWpGaD
Minocycline—IL1B—Allograft Rejection—IL10—ankylosing spondylitis	0.000739	0.00292	CbGpPWpGaD
Minocycline—IL1B—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000739	0.00292	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—IL17A—ankylosing spondylitis	0.000724	0.00286	CbGpPWpGaD
Minocycline—CASP3—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000719	0.00284	CbGpPWpGaD
Minocycline—IL1B—Folate Metabolism—CRP—ankylosing spondylitis	0.000717	0.00284	CbGpPWpGaD
Minocycline—IL1B—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000703	0.00278	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.000691	0.00273	CbGpPWpGaD
Minocycline—CASP1—Immune System—KIR3DL1—ankylosing spondylitis	0.000684	0.0027	CbGpPWpGaD
Minocycline—IL1B—IL27-mediated signaling events—TNF—ankylosing spondylitis	0.000684	0.0027	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—IL12B—ankylosing spondylitis	0.000673	0.00266	CbGpPWpGaD
Minocycline—IL1B—TCR Signaling Pathway—IL1A—ankylosing spondylitis	0.00067	0.00265	CbGpPWpGaD
Minocycline—IL1B—Cytokines and Inflammatory Response—TNF—ankylosing spondylitis	0.000664	0.00262	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000662	0.00262	CbGpPWpGaD
Minocycline—IL1B—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000651	0.00257	CbGpPWpGaD
Minocycline—CASP1—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.00065	0.00257	CbGpPWpGaD
Minocycline—IL1B—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	0.000643	0.00254	CbGpPWpGaD
Minocycline—CYCS—FAS pathway and Stress induction of HSP regulation—TNF—ankylosing spondylitis	0.000638	0.00252	CbGpPWpGaD
Minocycline—CASP3—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—ankylosing spondylitis	0.000625	0.00247	CbGpPWpGaD
Minocycline—MMP9—AP-1 transcription factor network—IL10—ankylosing spondylitis	0.000624	0.00247	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—CARD9—ankylosing spondylitis	0.000617	0.00244	CbGpPWpGaD
Minocycline—VEGFA—Oncostatin M Signaling Pathway—MMP3—ankylosing spondylitis	0.000612	0.00242	CbGpPWpGaD
Minocycline—IL1B—Methylprednisolone—Dexamethasone—ankylosing spondylitis	0.000606	0.0686	CbGdCrCtD
Minocycline—IL1B—Methylprednisolone—Betamethasone—ankylosing spondylitis	0.000606	0.0686	CbGdCrCtD
Minocycline—CASP1—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.0006	0.00237	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000599	0.00237	CbGpPWpGaD
Minocycline—CASP3—Spinal Cord Injury—IL1A—ankylosing spondylitis	0.000596	0.00235	CbGpPWpGaD
Minocycline—IL1B—Methylprednisolone—Triamcinolone—ankylosing spondylitis	0.000593	0.067	CbGdCrCtD
Minocycline—IL1B—Senescence and Autophagy in Cancer—IL1A—ankylosing spondylitis	0.000592	0.00234	CbGpPWpGaD
Minocycline—CASP3—Corticotropin-releasing hormone—TLR4—ankylosing spondylitis	0.000582	0.0023	CbGpPWpGaD
Minocycline—IL1B—Monoamine Transport—TNF—ankylosing spondylitis	0.000579	0.00229	CbGpPWpGaD
Minocycline—IL1B—Signaling by Interleukins—IL1A—ankylosing spondylitis	0.000579	0.00229	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000578	0.00228	CbGpPWpGaD
Minocycline—MMP9—Collagen formation—MMP3—ankylosing spondylitis	0.000574	0.00227	CbGpPWpGaD
Minocycline—CYCS—Ceramide signaling pathway—TNF—ankylosing spondylitis	0.000574	0.00227	CbGpPWpGaD
Minocycline—IL1B—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.00057	0.00225	CbGpPWpGaD
Minocycline—IL1B—Methylprednisolone—Prednisone—ankylosing spondylitis	0.000562	0.0636	CbGdCrCtD
Minocycline—CASP3—Amyotrophic lateral sclerosis (ALS)—TNF—ankylosing spondylitis	0.000558	0.00221	CbGpPWpGaD
Minocycline—MMP9—AP-1 transcription factor network—HLA-A—ankylosing spondylitis	0.00055	0.00217	CbGpPWpGaD
Minocycline—IL1B—Methylprednisolone—Prednisolone—ankylosing spondylitis	0.000549	0.0621	CbGdCrCtD
Minocycline—MMP9—Degradation of the extracellular matrix—MMP3—ankylosing spondylitis	0.000548	0.00217	CbGpPWpGaD
Minocycline—IL1B—Spinal Cord Injury—IL1A—ankylosing spondylitis	0.000539	0.00213	CbGpPWpGaD
Minocycline—IL1B—IL23-mediated signaling events—TNF—ankylosing spondylitis	0.000516	0.00204	CbGpPWpGaD
Minocycline—CASP3—FAS pathway and Stress induction of HSP regulation—TNF—ankylosing spondylitis	0.000515	0.00204	CbGpPWpGaD
Minocycline—CASP3—TWEAK Signaling Pathway—TNF—ankylosing spondylitis	0.000515	0.00204	CbGpPWpGaD
Minocycline—SLC22A11—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000501	0.00198	CbGpPWpGaD
Minocycline—CYCS—Caspase Cascade in Apoptosis—TNF—ankylosing spondylitis	0.0005	0.00198	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—IL1A—ankylosing spondylitis	0.000495	0.00196	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—IL10—ankylosing spondylitis	0.000492	0.00194	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000492	0.00194	CbGpPWpGaD
Minocycline—IL1B—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	0.000485	0.00192	CbGpPWpGaD
Minocycline—ALOX5—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.000481	0.0019	CbGpPWpGaD
Minocycline—CASP3—Spinal Cord Injury—TLR4—ankylosing spondylitis	0.000477	0.00189	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000476	0.00188	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000474	0.00187	CbGpPWpGaD
Minocycline—MMP9—Matrix Metalloproteinases—TNF—ankylosing spondylitis	0.000468	0.00185	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000468	0.00185	CbGpPWpGaD
Minocycline—SLC22A7—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000455	0.0018	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000449	0.00177	CbGpPWpGaD
Minocycline—CASP3—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	0.000448	0.00177	CbGpPWpGaD
Minocycline—MMP9—amb2 Integrin signaling—TNF—ankylosing spondylitis	0.000444	0.00176	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000434	0.00171	CbGpPWpGaD
Minocycline—IL1B—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	0.000433	0.00171	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000432	0.00171	CbGpPWpGaD
Minocycline—IL1B—Spinal Cord Injury—TLR4—ankylosing spondylitis	0.000432	0.00171	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.000432	0.00171	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000431	0.0017	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000429	0.00169	CbGpPWpGaD
Minocycline—CASP1—Apoptosis—TNF—ankylosing spondylitis	0.000428	0.00169	CbGpPWpGaD
Minocycline—IL1B—Immune System—KIR3DL1—ankylosing spondylitis	0.000428	0.00169	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL1R2—ankylosing spondylitis	0.000414	0.00164	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—IL1A—ankylosing spondylitis	0.000413	0.00163	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000409	0.00162	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000406	0.00161	CbGpPWpGaD
Minocycline—CASP3—Caspase Cascade in Apoptosis—TNF—ankylosing spondylitis	0.000403	0.00159	CbGpPWpGaD
Minocycline—IL1B—Vitamin B12 Metabolism—TNF—ankylosing spondylitis	0.000399	0.00158	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000399	0.00158	CbGpPWpGaD
Minocycline—CASP1—Immune System—ERAP1—ankylosing spondylitis	0.000393	0.00155	CbGpPWpGaD
Minocycline—CYCS—Cellular responses to stress—IL1A—ankylosing spondylitis	0.000388	0.00153	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000387	0.00153	CbGpPWpGaD
Minocycline—CYCS—Alzheimers Disease—TNF—ankylosing spondylitis	0.000385	0.00152	CbGpPWpGaD
Minocycline—SLC22A8—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000382	0.00151	CbGpPWpGaD
Minocycline—IL1B—Fluorometholone—Methylprednisolone—ankylosing spondylitis	0.000382	0.0432	CbGdCrCtD
Minocycline—IL1B—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	0.000379	0.0015	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000379	0.0015	CbGpPWpGaD
Minocycline—IL1B—Fluorometholone—Betamethasone—ankylosing spondylitis	0.000376	0.0425	CbGdCrCtD
Minocycline—IL1B—Fluorometholone—Dexamethasone—ankylosing spondylitis	0.000376	0.0425	CbGdCrCtD
Minocycline—IL1B—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.000375	0.00148	CbGpPWpGaD
Minocycline—IL1B—Fluorometholone—Triamcinolone—ankylosing spondylitis	0.000367	0.0415	CbGdCrCtD
Minocycline—CYCS—Apoptosis—TNF—ankylosing spondylitis	0.000367	0.00145	CbGpPWpGaD
Minocycline—CASP1—Immune System—CARD9—ankylosing spondylitis	0.000359	0.00142	CbGpPWpGaD
Minocycline—MMP9—TWEAK Signaling Pathway—TNF—ankylosing spondylitis	0.000358	0.00141	CbGpPWpGaD
Minocycline—IL1B—Fluorometholone—Prednisone—ankylosing spondylitis	0.000348	0.0394	CbGdCrCtD
Minocycline—IL1B—Fluorometholone—Prednisolone—ankylosing spondylitis	0.00034	0.0385	CbGdCrCtD
Minocycline—MMP9—Spinal Cord Injury—TLR4—ankylosing spondylitis	0.000331	0.00131	CbGpPWpGaD
Minocycline—CASP3—Extracellular matrix organization—MMP3—ankylosing spondylitis	0.000331	0.00131	CbGpPWpGaD
Minocycline—IL1B—Folate Metabolism—TNF—ankylosing spondylitis	0.000325	0.00128	CbGpPWpGaD
Minocycline—SLC22A6—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000319	0.00126	CbGpPWpGaD
Minocycline—CASP3—Allograft Rejection—TNF—ankylosing spondylitis	0.000311	0.00123	CbGpPWpGaD
Minocycline—CASP3—Alzheimers Disease—TNF—ankylosing spondylitis	0.000311	0.00123	CbGpPWpGaD
Minocycline—CASP3—Apoptosis—TNF—ankylosing spondylitis	0.000296	0.00117	CbGpPWpGaD
Minocycline—VEGFA—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	0.000289	0.00114	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000287	0.00113	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000285	0.00113	CbGpPWpGaD
Minocycline—IL1B—Allograft Rejection—TNF—ankylosing spondylitis	0.000281	0.00111	CbGpPWpGaD
Minocycline—IL1B—Alzheimers Disease—TNF—ankylosing spondylitis	0.000281	0.00111	CbGpPWpGaD
Minocycline—CASP3—TNF alpha Signaling Pathway—TNF—ankylosing spondylitis	0.000275	0.00109	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.00027	0.00107	CbGpPWpGaD
Minocycline—IL1B—Immune System—IL1R2—ankylosing spondylitis	0.000259	0.00102	CbGpPWpGaD
Minocycline—IL1B—Selenium Micronutrient Network—TNF—ankylosing spondylitis	0.000258	0.00102	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000255	0.00101	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Methylprednisolone—ankylosing spondylitis	0.000255	0.0288	CbGdCrCtD
Minocycline—IL1B—Budesonide—Betamethasone—ankylosing spondylitis	0.000251	0.0284	CbGdCrCtD
Minocycline—IL1B—Budesonide—Dexamethasone—ankylosing spondylitis	0.000251	0.0284	CbGdCrCtD
Minocycline—CASP1—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000246	0.000972	CbGpPWpGaD
Minocycline—IL1B—Immune System—ERAP1—ankylosing spondylitis	0.000246	0.000971	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Triamcinolone—ankylosing spondylitis	0.000245	0.0277	CbGdCrCtD
Minocycline—IL1B—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000237	0.000935	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Prednisone—ankylosing spondylitis	0.000233	0.0263	CbGdCrCtD
Minocycline—MMP9—Extracellular matrix organization—MMP3—ankylosing spondylitis	0.00023	0.000907	CbGpPWpGaD
Minocycline—IL1B—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	0.000229	0.000906	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000229	0.000906	CbGpPWpGaD
Minocycline—IL1B—Budesonide—Prednisolone—ankylosing spondylitis	0.000227	0.0257	CbGdCrCtD
Minocycline—CASP1—Immune System—HLA-C—ankylosing spondylitis	0.000226	0.000892	CbGpPWpGaD
Minocycline—CASP3—Spinal Cord Injury—TNF—ankylosing spondylitis	0.000225	0.000891	CbGpPWpGaD
Minocycline—IL1B—Immune System—CARD9—ankylosing spondylitis	0.000225	0.000888	CbGpPWpGaD
Minocycline—CYCS—Apoptosis—TNF—ankylosing spondylitis	0.000225	0.000888	CbGpPWpGaD
Minocycline—ALOX5—Selenium Micronutrient Network—TNF—ankylosing spondylitis	0.000218	0.00086	CbGpPWpGaD
Minocycline—IL1B—Spinal Cord Injury—TNF—ankylosing spondylitis	0.000204	0.000806	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—CRP—ankylosing spondylitis	0.000203	0.000801	CbGpPWpGaD
Minocycline—CYCS—Metabolism—B3GNT2—ankylosing spondylitis	0.000202	0.000799	CbGpPWpGaD
Minocycline—CASP1—Immune System—IL1RN—ankylosing spondylitis	0.000196	0.000775	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—TLR4—ankylosing spondylitis	0.000194	0.000767	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—IL1A—ankylosing spondylitis	0.000188	0.000745	CbGpPWpGaD
Minocycline—VEGFA—Allograft Rejection—TNF—ankylosing spondylitis	0.000187	0.00074	CbGpPWpGaD
Minocycline—CASP3—Apoptosis—TNF—ankylosing spondylitis	0.000181	0.000716	CbGpPWpGaD
Minocycline—CASP3—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.00018	0.000712	CbGpPWpGaD
Minocycline—IL1B—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	0.000179	0.000707	CbGpPWpGaD
Minocycline—CASP1—Immune System—CD79A—ankylosing spondylitis	0.000172	0.00068	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.00017	0.000671	CbGpPWpGaD
Minocycline—IL1B—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.000163	0.000645	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—TNF—ankylosing spondylitis	0.000156	0.000618	CbGpPWpGaD
Minocycline—IL1B—Dexamethasone—Methylprednisolone—ankylosing spondylitis	0.000156	0.0176	CbGdCrCtD
Minocycline—IL1B—Betamethasone—Methylprednisolone—ankylosing spondylitis	0.000156	0.0176	CbGdCrCtD
Minocycline—IL1B—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000154	0.000608	CbGpPWpGaD
Minocycline—IL1B—Betamethasone—Dexamethasone—ankylosing spondylitis	0.000153	0.0174	CbGdCrCtD
Minocycline—IL1B—Dexamethasone—Betamethasone—ankylosing spondylitis	0.000153	0.0174	CbGdCrCtD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000153	0.000606	CbGpPWpGaD
Minocycline—IL1B—Betamethasone—Triamcinolone—ankylosing spondylitis	0.00015	0.017	CbGdCrCtD
Minocycline—IL1B—Dexamethasone—Triamcinolone—ankylosing spondylitis	0.00015	0.017	CbGdCrCtD
Minocycline—IL1B—Betamethasone—Prednisone—ankylosing spondylitis	0.000142	0.0161	CbGdCrCtD
Minocycline—IL1B—Dexamethasone—Prednisone—ankylosing spondylitis	0.000142	0.0161	CbGdCrCtD
Minocycline—CASP1—Immune System—IL1A—ankylosing spondylitis	0.000141	0.000558	CbGpPWpGaD
Minocycline—IL1B—Immune System—HLA-C—ankylosing spondylitis	0.000141	0.000558	CbGpPWpGaD
Minocycline—CASP1—Immune System—CD40LG—ankylosing spondylitis	0.00014	0.000555	CbGpPWpGaD
Minocycline—IL1B—Betamethasone—Prednisolone—ankylosing spondylitis	0.000139	0.0157	CbGdCrCtD
Minocycline—IL1B—Dexamethasone—Prednisolone—ankylosing spondylitis	0.000139	0.0157	CbGdCrCtD
Minocycline—CASP1—Immune System—HLA-B—ankylosing spondylitis	0.000133	0.000527	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—B3GNT2—ankylosing spondylitis	0.000125	0.000492	CbGpPWpGaD
Minocycline—CASP1—Immune System—HLA-A—ankylosing spondylitis	0.000124	0.000489	CbGpPWpGaD
Minocycline—IL1B—Immune System—IL1RN—ankylosing spondylitis	0.000123	0.000484	CbGpPWpGaD
Minocycline—CASP1—Immune System—CRP—ankylosing spondylitis	0.000118	0.000466	CbGpPWpGaD
Minocycline—CASP1—Immune System—TLR4—ankylosing spondylitis	0.000113	0.000447	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.000109	0.000429	CbGpPWpGaD
Minocycline—IL1B—Immune System—CD79A—ankylosing spondylitis	0.000108	0.000425	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—PTGER4—ankylosing spondylitis	9.36e-05	0.00037	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	9.24e-05	0.000365	CbGpPWpGaD
Minocycline—IL1B—Immune System—IL1A—ankylosing spondylitis	8.82e-05	0.000349	CbGpPWpGaD
Minocycline—IL1B—Immune System—CD40LG—ankylosing spondylitis	8.77e-05	0.000347	CbGpPWpGaD
Minocycline—IL1B—Immune System—HLA-B—ankylosing spondylitis	8.34e-05	0.00033	CbGpPWpGaD
Minocycline—VEGFA—Dexamethasone—Methylprednisolone—ankylosing spondylitis	8.33e-05	0.00942	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Methylprednisolone—ankylosing spondylitis	8.33e-05	0.00942	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Dexamethasone—ankylosing spondylitis	8.2e-05	0.00927	CbGdCrCtD
Minocycline—VEGFA—Dexamethasone—Betamethasone—ankylosing spondylitis	8.2e-05	0.00927	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Triamcinolone—ankylosing spondylitis	8.01e-05	0.00906	CbGdCrCtD
Minocycline—VEGFA—Dexamethasone—Triamcinolone—ankylosing spondylitis	8.01e-05	0.00906	CbGdCrCtD
Minocycline—IL1B—Immune System—HLA-A—ankylosing spondylitis	7.73e-05	0.000305	CbGpPWpGaD
Minocycline—VEGFA—Dexamethasone—Prednisone—ankylosing spondylitis	7.6e-05	0.00859	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Prednisone—ankylosing spondylitis	7.6e-05	0.00859	CbGdCrCtD
Minocycline—VEGFA—Dexamethasone—Prednisolone—ankylosing spondylitis	7.42e-05	0.00839	CbGdCrCtD
Minocycline—VEGFA—Betamethasone—Prednisolone—ankylosing spondylitis	7.42e-05	0.00839	CbGdCrCtD
Minocycline—IL1B—Immune System—CRP—ankylosing spondylitis	7.37e-05	0.000291	CbGpPWpGaD
Minocycline—IL1B—Immune System—TLR4—ankylosing spondylitis	7.07e-05	0.000279	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—MMP3—ankylosing spondylitis	6.66e-05	0.000263	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PTGER4—ankylosing spondylitis	6.5e-05	0.000257	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PTGER4—ankylosing spondylitis	5.64e-05	0.000223	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—TNF—ankylosing spondylitis	4.98e-05	0.000197	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—MMP3—ankylosing spondylitis	4.62e-05	0.000183	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—TNF—ankylosing spondylitis	4.32e-05	0.000171	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—MMP3—ankylosing spondylitis	4.01e-05	0.000159	CbGpPWpGaD
